Replimune Group, Inc.

Stocks

REPL

US76029N1063

Market Closed - Nasdaq 16:00:00 2026-09-17 EDT			5-day change	1st Jan Change
12.87 ^USD	-0.69%		-2.79%	+32.41%

09-15	Replimune Group, Inc. - Shareholder/Analyst Call
08-18	Trump picks White House adviser Heidi Overton to run FDA, source says	RE

Transcript : Replimune Group, Inc. - Shareholder/Analyst Call

Published on 08/07/2026 at 08:52 am EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the TUDRIQEV FDA Accelerated Approval Call. [Operator Instructions] Please be advised that today's

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Replimune Group, Inc.

09-15	Replimune Group, Inc. - Shareholder/Analyst Call
08-18	Trump picks White House adviser Heidi Overton to run FDA, source says	RE
08-14	Replimune Group, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
08-14	Replimune Group, Inc. Announces Appointment of Michelle Dinapoli to Chief Commercial Officer, Effective August 18, 2026	CI
08-14	Replimune Fiscal Q1 Net Loss Narrows	MT
08-14	Earnings Flash (REPL) Replimune Posts Fiscal Q1 Net Loss $0.72 a Share, vs. FactSet Est of $0.66 Loss	MT
08-10	Replimune Prices $150 Million Offering	MT
08-07	Replimune Group, Inc. - Shareholder/Analyst Call
08-07	Wedbush Upgrades Replimune Group to Outperform From Neutral, Adjusts PT to $19 From $12	MT
08-06	US FDA approves Replimune's skin cancer drug after prior rejections	RE
08-06	Replimune Group Announces FDA Accelerated Approval Of TUDRIQEV In Combination With Nivolumab For Unresectable Advanced Cutaneous Melanoma After Progression On An Anti-PD-1 Based Regimen	CI
08-04	Leerink Partners Upgrades Replimune Group to Outperform From Market Perform, Adjusts Price Target to $17 From $11	MT
07-31	Top Midday Gainers	MT
07-31	Replimune's RP1 Likely to Win US FDA Approval for Advanced Melanoma, Wedbush Says	MT
07-31	Cantor Fitzgerald Upgrades Replimune to Overweight From Neutral	MT